Username:    Password:      Remember me       

Cancer Forums

A website for discussions about any type of cancer, including lung cancer, breast cancer, mesothelioma, prostate cancer, laryngeal cancer, leukemia, lymphoma, multiple myeloma and others

SearchSearch   DigestsEmail Digests     Register to postRegister to post   ProfileProfile   Check private messagesCheck private messages   Log inLog in 
Lung Cancer Vaccine What is this ?

 
Post new topic   Reply to topic    Cancer Forums Forum Index -> Lung Cancer Forum


Author
vancity
New User


Joined: 13 Mar 2006
Posts: 2
PostPosted: Mon Mar 13, 2006 1:56 am    Post subject: Lung Cancer Vaccine Reply with quote
The Company also announced that median survival for patients with Stage IIIB locoregional non-small cell lung cancer who received BLP25 Liposome Vaccine (L-BLP25) in a phase 2b study has been determined [30.6 months compared with 13.3 months for the unvaccinated group].
BLP25 has been taken over by Merck KgaA/EMD Pharmaceuticals under the name Stimuvax. Phase III Clinical Trial to start mid 2006. I strongly recommend anyone interested in more information or participating go the following link.
http://www.blp25.net/home.jsp
password: vaccine
just fill in the rest and your in.
Back to top
vancity
New User


Joined: 13 Mar 2006
Posts: 2
PostPosted: Tue Mar 28, 2006 12:16 am    Post subject: Update Reply with quote
Stimuvax® (formerly referred to as BLP25 Liposome Vaccine) – mimics the mucin MUC1, which is present on many tumors On January 26, 2006, Merck KGaA and its co-development partner Biomira Inc. announced the signing of a binding letter of intent to amend the licensing agreement for Stimuvax. The amended agreement gives Merck global development and marketing rights to the vaccine except in Canada, where the companies share rights to the vaccine. Under the letter of intent, Merck takes over full responsibility – both administrative and financial – for development and commercialization of Stimuvax, including the planned Phase III trial in NSCLC, which remains on track to start this summer. Survival results from the Phase IIB trial in Stage IIIB and IV non-small cell lung cancer (NSCLC) patients indicated a 4.4 month longer median survival for patients randomized to the Stimuvax arm (88 patients) compared to the best supportive care (BSC) arm (83 patients). The greatest benefit was observed in vaccinated patients with Stage IIIB locoregional NSCLC, which makes up approximately 25 percent of patients with this form of cancer. Median survival – reached for the vaccinated subset of Stage IIIb locoregional patients in October 2005 – was 30.6 months compared to 13.3 months observed for the same stage patients who did not receive the vaccine, a difference of 17.3 months. Though not statistically significant, the survival update provides additional clarity for statistical considerations for the planned Phase III trial.1,2
Back to top


Display posts from previous:   
Post new topic   Reply to topic    Cancer Forums Forum Index -> Lung Cancer Forum All times are GMT - 5 Hours
Page 1 of 1

 
Jump to:  
You cannot post new topics in this forum
You cannot reply to topics in this forum
You cannot edit your posts in this forum
You cannot delete your posts in this forum
You cannot vote in polls in this forum
Download our Toolbar



About the author
E-mail webmaster
Terms, conditions and privacy policy		 We subscribe to the HONcode principles of the HON Foundation. Click to verify. We subscribe to the HONcode principles. Verify here. All content and posts are copyright.
Powered by phpBB © 2001, 2002 phpBB Group